OGT 918: Phase I/II

OGS published in The Lancet results of its 1-year, 28-patient international Phase I/II open label trial showing improvements in patients receiving 100 mg OGT 918 three times per day. Patients in the trial were either unable or unwilling to receive intravenous glucocerebrosidase enzyme replacement therapy for the disease. ...